| Ibrutinib dose intensity in high‐risk chronic lymphocytic leukemia G Forestieri, L Terzi di Bergamo, M Deodato, AM Frustaci, R Moia, ... Hematological Oncology 40 (5), 1100-1104, 2022 | 2 | 2022 |
| Clinical utility of circulating tumor DNA qualification and quantification in classical Hodgkin lymphoma MC Pirosa, A Bruscaggin, L Terzi Di Bergamo, M Salehi, V Spina, K Pini, ... Hematological Oncology 41, 319-321, 2023 | 1 | 2023 |
| S225: CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER AT BASELINE AND IMPROVES THE ACCURACY OF INTERIM PET IN CLASSIC HODGKIN LYMPHOMA MC Pirosa, A Bruscaggin, LT di Bergamo, M Salehi, K Pini, V Spina, ... HemaSphere 6, 126-127, 2022 | 1 | 2022 |
| Circulating tumor DNA of classical Hodgkin lymphoma. MC Pirosa, A Bruscaggin, L Terzi di Bergamo, M Salehi, V Spina, K Pini, ... Journal of Clinical Oncology 41 (16_suppl), 7516-7516, 2023 | | 2023 |
| HL-370 Fragmentóme Profiling Reveals Distinct Molecular Subgroups of Classic Hodgkin Lymphoma LT di Bergamo, MC Pirosa, A Bruscaggin, M Salehi, V Spina, K Pini, ... Clinical Lymphoma Myeloma and Leukemia 22, S348-S349, 2022 | | 2022 |
| Poster: HL-370 Fragmentome Profiling Reveals Distinct Molecular Subgroups of Classic Hodgkin Lymphoma LT di Bergamo, MC Pirosa, A Bruscaggin, M Salehi, V Spina, K Pini, ... Clinical Lymphoma, Myeloma and Leukemia 22, S162, 2022 | | 2022 |
